We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Genocea’s therapeutic genital herpes vaccine posted new phase 2b data that support the candidate's "groundbreaking potential" as possibly the first genital herpes treatment advancement in more than 20 years, the biotech's CEO says.